Literature DB >> 27791178

Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.

Srisathiyanarayanan Dharmaiah1, Lakshman Bindu1, Timothy H Tran1, William K Gillette1, Peter H Frank1, Rodolfo Ghirlando2, Dwight V Nissley1, Dominic Esposito1, Frank McCormick3,4, Andrew G Stephen1, Dhirendra K Simanshu3.   

Abstract

Farnesylation and carboxymethylation of KRAS4b (Kirsten rat sarcoma isoform 4b) are essential for its interaction with the plasma membrane where KRAS-mediated signaling events occur. Phosphodiesterase-δ (PDEδ) binds to KRAS4b and plays an important role in targeting it to cellular membranes. We solved structures of human farnesylated-methylated KRAS4b in complex with PDEδ in two different crystal forms. In these structures, the interaction is driven by the C-terminal amino acids together with the farnesylated and methylated C185 of KRAS4b that binds tightly in the central hydrophobic pocket present in PDEδ. In crystal form II, we see the full-length structure of farnesylated-methylated KRAS4b, including the hypervariable region. Crystal form I reveals structural details of farnesylated-methylated KRAS4b binding to PDEδ, and crystal form II suggests the potential binding mode of geranylgeranylated-methylated KRAS4b to PDEδ. We identified a 5-aa-long sequence motif (Lys-Ser-Lys-Thr-Lys) in KRAS4b that may enable PDEδ to bind both forms of prenylated KRAS4b. Structure and sequence analysis of various prenylated proteins that have been previously tested for binding to PDEδ provides a rationale for why some prenylated proteins, such as KRAS4a, RalA, RalB, and Rac1, do not bind to PDEδ. Comparison of all four available structures of PDEδ complexed with various prenylated proteins/peptides shows the presence of additional interactions due to a larger protein-protein interaction interface in KRAS4b-PDEδ complex. This interface might be exploited for designing an inhibitor with minimal off-target effects.

Entities:  

Keywords:  KRAS4b; KRAS–PDEδ complex; phosphodiesterase-δ; prenylation; protein–protein interaction

Mesh:

Substances:

Year:  2016        PMID: 27791178      PMCID: PMC5098621          DOI: 10.1073/pnas.1615316113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  Mutational and biochemical analysis of plasma membrane targeting mediated by the farnesylated, polybasic carboxy terminus of K-ras4B.

Authors:  M O Roy; R Leventis; J R Silvius
Journal:  Biochemistry       Date:  2000-07-18       Impact factor: 3.162

2.  Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.

Authors:  T Scott Reid; Kimberly L Terry; Patrick J Casey; Lorena S Beese
Journal:  J Mol Biol       Date:  2004-10-15       Impact factor: 5.469

3.  The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins.

Authors:  Anchal Chandra; Hernán E Grecco; Venkat Pisupati; David Perera; Liam Cassidy; Ferdinandos Skoulidis; Shehab A Ismail; Christian Hedberg; Michael Hanzal-Bayer; Ashok R Venkitaraman; Alfred Wittinghofer; Philippe I H Bastiaens
Journal:  Nat Cell Biol       Date:  2011-12-18       Impact factor: 28.824

4.  K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif.

Authors:  Frederick D Tsai; Mathew S Lopes; Mo Zhou; Helen Court; Odis Ponce; James J Fiordalisi; Jessica J Gierut; Adrienne D Cox; Kevin M Haigis; Mark R Philips
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

5.  Recorded scan times can limit the accuracy of sedimentation coefficients in analytical ultracentrifugation.

Authors:  Huaying Zhao; Rodolfo Ghirlando; Grzegorz Piszczek; Ute Curth; Chad A Brautigam; Peter Schuck
Journal:  Anal Biochem       Date:  2013-02-28       Impact factor: 3.365

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

8.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

9.  PDE6δ-mediated sorting of INPP5E into the cilium is determined by cargo-carrier affinity.

Authors:  Eyad Kalawy Fansa; Stefanie Kristine Kösling; Eldar Zent; Alfred Wittinghofer; Shehab Ismail
Journal:  Nat Commun       Date:  2016-04-11       Impact factor: 14.919

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  62 in total

1.  The RAS-interacting chaperone UNC119 drives the RASSF6-MDM2-p53 axis and antagonizes RAS-mediated malignant transformation.

Authors:  Takanobu Shimizu; Takeshi Nakamura; Hironori Inaba; Hiroaki Iwasa; Junichi Maruyama; Kyoko Arimoto-Matsuzaki; Takao Nakata; Hiroshi Nishina; Yutaka Hata
Journal:  J Biol Chem       Date:  2020-06-18       Impact factor: 5.157

Review 2.  Posttranslational Modifications of RAS Proteins.

Authors:  Ian Ahearn; Mo Zhou; Mark R Philips
Journal:  Cold Spring Harb Perspect Med       Date:  2018-11-01       Impact factor: 6.915

Review 3.  KRAS Alleles: The Devil Is in the Detail.

Authors:  Kevin M Haigis
Journal:  Trends Cancer       Date:  2017-09-12

4.  The two splice variant forms of Cdc42 exert distinct and essential functions in neurogenesis.

Authors:  Makoto Endo; Joseph E Druso; Richard A Cerione
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

5.  Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.

Authors:  Andrew M Waters; Irem Ozkan-Dagliyan; Angelina V Vaseva; Nicole Fer; Leslie A Strathern; G Aaron Hobbs; Basile Tessier-Cloutier; William K Gillette; Rachel Bagni; Gordon R Whiteley; James L Hartley; Frank McCormick; Adrienne D Cox; Peter J Houghton; David G Huntsman; Mark R Philips; Channing J Der
Journal:  Sci Signal       Date:  2017-09-26       Impact factor: 8.192

6.  Targeting the α4-α5 interface of RAS results in multiple levels of inhibition.

Authors:  Russell Spencer-Smith; Lie Li; Sheela Prasad; Akiko Koide; Shohei Koide; John P O'Bryan
Journal:  Small GTPases       Date:  2017-12-31

Review 7.  New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics.

Authors:  Dominic Esposito; Andrew G Stephen; Thomas J Turbyville; Matthew Holderfield
Journal:  Semin Cancer Biol       Date:  2018-02-09       Impact factor: 15.707

Review 8.  RAS Proteins and Their Regulators in Human Disease.

Authors:  Dhirendra K Simanshu; Dwight V Nissley; Frank McCormick
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

9.  GEF mechanism revealed by the structure of SmgGDS-558 and farnesylated RhoA complex and its implication for a chaperone mechanism.

Authors:  Hikaru Shimizu; Sachiko Toma-Fukai; Kenji Kontani; Toshiaki Katada; Toshiyuki Shimizu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-06       Impact factor: 11.205

Review 10.  Oncogenic Ras Isoforms Signaling Specificity at the Membrane.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Cancer Res       Date:  2017-12-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.